Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: A closed debate?

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5095-5100

  Kelada, Olivia ^a   Marignol, Laure ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Breast cancer patients; Chemotherapy induced anemia; Erythropoietin stimulating agents

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

BLOOD TRANSFUSION; BLOOD VISCOSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; FOOD AND DRUG ADMINISTRATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; TREATMENT DURATION;

ANEMIA; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HEMATINICS; HUMANS; NEOPLASM METASTASIS;

EID: 84904718819     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1730-6     Document Type: Review

References (43)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306. doi:10.1016/j.ejca.2004. 06.019. (Pubitemid 39348881)
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616-34. (Pubitemid 29479929)
3. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26(4):303-11. doi:10.1053/ctrv.2000.0181. (Pubitemid 30604041)
4. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol. 2009;72(2):170-9. doi:10.1016/j.critrevonc.2009.03.004.
5. Khan FA, Shukla AN, Joshi SC. Anaemia and cancer treatment: a conceptual change. Singapore Med J. 2008;49(10):759-64.
6. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med. 2009;60:181-92. doi:10.1146/annurev.med.60.050307.110718.
7. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4(8):459-60. (Pubitemid 37009952)
8. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol. 1997;15(7):2715-21. (Pubitemid 27289905)
9. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 2008;26(4):592-8. doi:10.1200/JCO.2007.11.5378. (Pubitemid 351264353)
10. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 2007;43(2):258-70. doi:10.1016/j.ejca.2006. 10.014. (Pubitemid 46127840)
11. Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol. 2003;30(5 Suppl 16):174-84. (Pubitemid 37433409)
12. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009;3, CD007303. doi:10.1002/14651858.CD007303.pub2.
13. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914-24. doi:10.1001/jama.299.8.914. (Pubitemid 351397066)
14. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12, CD003407. doi:10.1002/14651858.CD003407.pub5.
15. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med. 1975;6(1):61-4.
16. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91(21):1829-46.
17. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318(7):404-7. doi:10.1056/NEJM198802183180703. (Pubitemid 18044179)
18. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984;54(7):1264-8. (Pubitemid 14003521)
19. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;13 Suppl 3:11-5. doi:10.1634/theoncologist. 13-S3-11.
20. FDA. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. 2011.
21. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960-72. doi:10.1200/JCO.2005.06.150.
22. Hudis CA, Vogel CL, Gralow JR, Williams D. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer. 2005;6(2):132-42. (Pubitemid 40975609)
23. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013;105(14):1018-26. doi:10.1093/jnci/djt145.
24. O'Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5(6):439-46.
25. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol. 2011;22(9):1999-2006. doi:10.1093/annonc/mdq713.
26. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2597-605. doi:10.1200/JCO.2004.12.027. (Pubitemid 46179448)
27. Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, et al. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist. 2010;15(9):935-43. doi:10.1634/theoncologist.2009-0279.
28. Continuing Reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESA) Administered for the treatment of anemia associated with cancer chemotherapy [database on the Internet] 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4301b2-02-FDA.pdf. Accessed 28 Sept 2013.
29. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer. 2012;106(7):1249-58. doi:10.1038/bjc.2012. 42.
30. Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res. 2008;14(11):3242-7. doi:10.1158/1078- 0432.CCR-07-1872.
31. Clavo B. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol. 2007;25(11):1447-8. doi:10.1200/JCO.2006.09. 9713. (Pubitemid 46706900)
32. Quirt I, Kovacs M, Couture F, Turner AR, Noble M, Burkes R, et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience. Oncologist. 2006;11(1):73-82. doi:10.1634/ theoncologist.11-1-73. (Pubitemid 43152689)
33. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19(11):2875-82. (Pubitemid 32538197)
34. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a surveillance, epidemiology, and end results-Medicare study. Cancer. 2011;117(16):3641-9. doi:10.1002/cncr.25972.
35. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res. 2011;17(19):6151-62. doi:10.1158/1078-0432.CCR-10-3298.
36. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20(19):4083-107.
37. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist. 1996;1(3):140-50. (Pubitemid 126669230)
38. Wright JD, Neugut AI, Wilde ET, Buono DL, Malin J, Tsai WY, et al. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. J Clin Oncol. 2011;29(25):3408-18. doi:10.1200/JCO.2010.34.5462.
39. Henry DH, Langer CJ, McKenzie RS, Piech CT, Senbetta M, Schulman KL, et al. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer. 2012;20(9):2089-96. doi:10.1007/s00520-011-1318-2.
40. Ray-Coquard I, Morere JF, Scotte F, Cals L, Antoine EC. Management of anemia in advanced breast and lung cancer patients in daily practice: results of a French survey. Adv Ther. 2012;29(2):124-33. doi:10.1007/s12325-011-0093-2.
41. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol. 2005;6(11):856-63. doi:10.1016/S1470-2045(05) 70394-6. (Pubitemid 41614797)
42. Luporsi E, Mahi L, Morre C, Wernli J, de Pouvourville G, Bugat R. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ. 2012;15(2):225 -32. doi:10.3111/13696998.2011.639823.
43. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolismin patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101(4):762-9.